Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma

被引:1
作者
Shao, Weilin [1 ]
Feng, Yan [1 ]
Huang, Jin [1 ]
Li, Tingyu [3 ]
Gao, Shengguai [3 ]
Yang, Yihao [1 ]
Li, Dongqi [1 ]
Yang, Zuozhang [1 ]
Yao, Zhihong [1 ,2 ]
机构
[1] Kunming Med Univ, Yunnan Canc Hosp, Bone & Soft Tissue Tumours Res Ctr Yunnan Prov, Yunnan Canc Ctr,Affiliated Hosp 3,Dept Orthopaed, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China
[2] Kunming Med Univ, Yunnan Canc Hosp, Yunnan Canc Ctr, Affiliated Hosp 3,Dept Canc,Res Inst, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China
[3] Kunming Med Univ, Clin Oncol Inst, Kunming 650500, Yunnan, Peoples R China
来源
OPEN LIFE SCIENCES | 2024年 / 19卷 / 01期
基金
美国国家科学基金会;
关键词
osteosarcoma; PI3K/AKT/mTOR; ncRNAs; biomarkers; therapeutic targets; PROMOTES CELL-PROLIFERATION; SIGNALING PATHWAY; NONCODING RNA; CISPLATIN RESISTANCE; DOWN-REGULATION; TUMOR PROGRESSION; CIRCULAR RNAS; UP-REGULATION; GROWTH; INVASION;
D O I
10.1515/biol-2022-0936
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents, and is characterized by high heterogeneity, high malignancy, easy metastasis, and poor prognosis. Recurrence, metastasis, and multidrug resistance are the main problems that limit the therapeutic effect and prognosis of OS. PI3K/AKT/mTOR signaling pathway is often abnormally activated in OS tissues and cells, which promotes the rapid development, metastasis, and drug sensitivity of OS. Emerging evidence has revealed new insights into tumorigenesis through the interaction between the PI3K/AKT/mTOR pathway and non-coding RNAs (ncRNAs). Therefore, we reviewed the interactions between the PI3K/AKT/mTOR pathway and ncRNAs and their implication in OS. These interactions have the potential to serve as cancer biomarkers and therapeutic targets in clinical applications.
引用
收藏
页数:14
相关论文
共 50 条
[41]   Effect of the Notch1-mediated PI3K-Akt-mTOR pathway in human osteosarcoma [J].
Zhang, Kexiang ;
Wu, Song ;
Wu, Hongwei ;
Liu, Li ;
Zhou, Jiahui .
AGING-US, 2021, 13 (17) :21090-21101
[42]   Genipin Inhibits the Development of Osteosarcoma through PI3K/AKT Signaling Pathway [J].
Huang, Xiongjie ;
Jiwa, Habu ;
Xu, Jingtao ;
Zhang, Jun ;
Huang, Yanran ;
Luo, Xiaoji .
CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (16) :1300-1310
[43]   Ferulic acid inhibits proliferation and promotes apoptosis via blockage of PI3K/Akt pathway in osteosarcoma cell [J].
Wang, Ting ;
Gong, Xia ;
Jiang, Rong ;
Li, Hongzhong ;
Du, Weimin ;
Kuang, Ge .
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (02) :968-980
[44]   The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers [J].
Paplomata, Elisavet ;
O'Regan, Ruth .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (04) :154-166
[45]   Aclidinium bromide inhibits proliferation of osteosarcoma cells through regulation of PI3K/Akt pathway [J].
Li, Z-Z ;
Wang, Y-L ;
Yu, Y-H ;
Xing, Y-L ;
Ji, X-F .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (01) :105-112
[46]   PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer [J].
Li, HaiXia ;
Zeng, JianFang ;
Shen, Keng .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2014, 290 (06) :1067-1078
[47]   Licochalcone A inhibits PI3K/Akt/mTOR signaling pathway activation and promotes autophagy in breast cancer cells [J].
Xue, Lei ;
Zhang, Wei-Jie ;
Fan, Qing-Xia ;
Wang, Liu-Xing .
ONCOLOGY LETTERS, 2018, 15 (02) :1869-1873
[48]   Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer [J].
Woo, S-U ;
Sangai, T. ;
Akcakanat, A. ;
Chen, H. ;
Wei, C. ;
Meric-Bernstam, F. .
ONCOGENESIS, 2017, 6 :e385-e385
[49]   The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis [J].
Tehranian, Cedric ;
Fankhauser, Laura ;
Harter, Patrick N. ;
Ratcliffe, Colin D. H. ;
Zeiner, Pia S. ;
Messmer, Julia M. ;
Hoffmann, Dirk C. ;
Frey, Katharina ;
Westphal, Dana ;
Ronellenfitsch, Michael W. ;
Sahai, Erik ;
Wick, Wolfgang ;
Karreman, Matthia A. ;
Winkler, Frank .
NEURO-ONCOLOGY, 2022, 24 (02) :213-225
[50]   PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress [J].
Wu, P. ;
Hu, Y-Z .
CURRENT MEDICINAL CHEMISTRY, 2010, 17 (35) :4326-4341